P454: VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
Constantin Schmidt(MRC Biostatistics Unit), Sascha Dietrich(European Molecular Biology Organization), Peter‐Martin Bruch(European Molecular Biology Organization), Maike Janssen(Heidelberg University), Daniel Heid(Heidelberg University), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Maximilian Felix Blank(Heidelberg University), Simon Renders(Heidelberg Institute for Stem Cell Technology and Experimental Medicine), Katharina Weidenauer(Heidelberg University), Christoph Kolb(University Hospital Heidelberg), Maximilian Knoll(University Hospital Heidelberg), Birgit Besenbeck(Heidelberg University), Friederike Stölzel(University Hospital Carl Gustav Carus), Sophie A. Herbst(German Cancer Research Center), Alexander Waclawiczek(German Cancer Research Center), Margarete A. Fabre(University of Cambridge), Muxin Gu(Wellcome/MRC Cambridge Stem Cell Institute), Irmela Jeremias(Helmholtz Zentrum München), R. Schlenk(University Hospital Ulm), Christian Rohde(Heidelberg University), Stefanie Göllner(Heidelberg University), Uwe Platzbecker(National Center for Tumor Diseases), Simon Raffel(Heidelberg University), Andreas Trumpp(German Cancer Research Center), Hubert Serve(Goethe University Frankfurt), Lisa Vierbaum(Heidelberg University), Jeroen Krijgsveld(German Cancer Research Center), Tim Sauer(Heidelberg University), Binje Vick(Helmholtz Zentrum München), Caroline Pabst(European Molecular Biology Organization)
Cited by 0
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The Ecoresponsive Genome of <i>Daphnia pulex</i>
|Science|2011|1.2k